(Nasdaq: MGRX) Profile

OUR NEW PROFILE IS:   (NASDAQ: MGRX)

52% OF MEN EXPERIENCE SOME FORM OF ERECTILE DYSFUNCTION THROUGHOUT THEIR LIFE AND THAT TOTAL INCREASES ANYWHERE FROM 5-15% BETWEEN AGES 40 AND 70

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

MGRX EXPERIENCED SEQUENTIAL REVENUE GROWTH OF 28.8% FROM Q1 TO Q2, 42.5% FROM Q2 TO Q3, AND 59% FROM Q1 TO Q3

SUBSCRIPTION SALES INCREASED 65% FROM Q1 TO Q3, WITH Q2 TO Q3 SEQUENTIAL GROWTH OF 47%

MANGOCEUTICALS, INC.’S DEBUT COMMERCIAL SURPASSES 9.3 MILLION VIEWS ON YOUTUBE

*****BREAKING NEWS RELEASED THIS MORNING*****

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

THE DALLAS BASED, DIRECT-TO-CONSUMER TELEMEDICINE COMPANY SECURES MARKETING AGREEMENT WITH MARIUS PHARMACEUTICALS BRINGING KYZATREX TO THE TELEHEALTH MARKET AS ‘PRIME’ BY MANGORX

Dallas, Texas & Raleigh, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals (“Marius”) to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, ‘PRIME’ by MangoRx.

PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally–as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.

TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body’s natural diurnal rhythm allowing for peak performance early in the day.

Twice daily oral TRTs offer painless administration, promote steady absorption, lower SHGB levels, increase free T levels to give the body more usable testosterone, and work with the body’s natural diurnal rhythm. Oral softgels are also convenient, mess-free, and discreet.

Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.”

PRIME by MangoRx will bring KYZATREX to patients spanning 48 states through the Company’s telemedicine platform, which is optimized to deliver a smooth medical prescription process, including blood work and synchronous telehealth visits with a fully licensed prescribing physician. Orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx’s URAC accredited mail order partner pharmacy directly to the patient’s doorstep.

Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with our established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. We are extremely fortunate to be working with Marius and to be one of only a few companies with access to this innovative product. With our established marketing and telemedicine infrastructure in place, we are ready to hit the ground running and take PRIME to patients in need across the country next month.”

Testosterone deficiency affects approximately four in ten men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society.3,4 Between 10% and 40% of men worldwide suffer from low testosterone levels.5

_____________________

Hello Everyone,

We saw a slew of double digit winners in November that we profiled here on the newsletter.  It was a tremendous month for us here on our newsletter.  If you have been following then you already know.

We have a new profile for today that we want you to research right away.

Pull up MGRX immediately.

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”).

Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

Mangoceuticals is making waves in the men’s health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers.

The men’s health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.

Beyond product offerings, Mangoceuticals understands the importance of education and information in men’s health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men’s health.

MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men’s health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep.

The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of ‘intimate well-being’ is an enjoyable experience.

Mango (Man-Go)

Mango, Mangoceuticals’ flagship product, is a groundbreaking solution designed to address men’s unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.

Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED.

Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men’s health and wellness products to new potential customers.

Mango is now available in 44 states, including Nevada and the District of Columbia.

MANGOCEUTICALS, INC. PROVIDES UPDATE TO SHAREHOLDERS ON Q3 ACHIEVEMENTS AND GUIDANCE ON YEAR END AND NEAR-TERM INITIATIVE

Dallas, Texas, Oct. 19, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to provide the following updates to current and prospective shareholders on the Company’s recent 3rd quarter achievements, along with guidance on year end and near-term initiatives. MangoRx is pleased to report on the following topics:

Year to Date Company Achievements (through September 30, 2023)

• Revenue Growth: The Company experienced sequential revenue growth of 28.8% from Q1 to Q2, 42.5% from Q2 to Q3, and 59% from Q1 to Q3. We attribute this growth to three primary factors: 1) the growing prominence of the Mango brand, 2) the Company’s aggressive marketing efforts through digital initiatives as well as sponsorships and promotions with Barstool Sports and the various podcast platforms launched with Audacy (as referenced in our press release dated September 6, 2023), and 3) funds raised in our initial public offering.
• Customer Acquisition: To date, we have successfully onboarded a rapidly growing customer base with an Average Order Value (AOV) of $105. Our goal is to continuously increase our customer base through additional prospecting and retargeting efforts. We have also launched an aggressive email marketing campaign to reach out to customer leads that have expressed interest in our products. To date, we have received positive results and plan to continue these efforts on an ongoing basis.
• Customer Subscriptions and Refills: Historically, subscribing customers have accounted for approximately 10% of all new orders with an Average Order Value (AOV) of approximately $130. Subscription sales increased 65% from Q1 to Q3, with Q2 to Q3 sequential growth of 47%, demonstrating an accelerating growth curve.

Additionally, many of our subscribing customers manually refill additional orders prior to receiving their scheduled auto-refill prescriptions, which we believe reflects the strong value-add role our Mango ED products have for our customers. Our goal is to grow the share of new orders that come from subscribing customers from 10% to 20-25%, which if successful, we expect will drive greater predictability and growth in revenues and cash flow, allowing the Company to invest even more aggressively in new customer acquisition.

• New Orders and Refills: For the nine-months ending September 30, 2023, new orders accounted for 76% of total revenues while refills/auto-refills accounted for 24% of total revenues. Sales from refills/auto-refills have grown sequentially by more than 50% over the past two consecutive quarters.

4th Quarter Goals and Initiatives

• New Men’s Health Product Categories: The Company has developed, and is in the process of developing, new men’s health and wellness pharmaceutical grade products expected to be launched and marketed and made available on www.MangoRx.com through our telemedicine portal. These product categories include, but are not limited to: hair loss, weight loss, performance, and various hormone therapies.

The Company has been working with internal product developers, third-party software developers, packaging vendors, marketing agencies, doctors’ networks, and the Company’s related-party compounding pharmacy, to ensure the timely and successful launch of these new and innovative products. The Company anticipates launching at least one additional product category by the end of the 4th quarter or the first quarter of 2024, funding permitted.

• New Web Design and User Experience: The Company has undertaken a complete redesign of its website, www.MangoRx.com. Currently, the Company’s website is singularly geared toward its erectile dysfunction Mango products. As the Company expands into new product categories, a newer design and user interface experience is necessary for the promotion and marketing of those new products. The Company anticipates launching its new web presence by the end of the 4th quarter.
• Launch of Affiliate Marketing Program: The Company is extremely pleased with the launch of its Affiliate Marketing Program, which allows various companies, influencers, and publishers to market and sell MangoRx products as an affiliate. Interested parties can sign up to become an affiliate at www.MangoRevenue.com, where they will have access to Company approved media, tools, and content to use on their own marketing platforms. If a purchase is made using their unique link or code, these affiliates are paid a commission on each product sold. Since launching the program in early October 2023, the Company has already signed up 100 affiliates in short order and has a goal of achieving 500 affiliates by the end of 2023.

The Company estimates that a well-executed and managed affiliate marketing program may be able to drive up to 20% of the Company’s overall gross revenues.

• Ongoing Marketing Initiatives: The Company has recently retained digital marketing agency Accelerated Digital Media (ADM), a digital media and marketing agency that specifically focuses on direct-to-consumer telemedicine and pharmaceutical brands. With clients including NURX, TalkSpace, and Keeps, management believes that the ADM team has the skills necessary to launch and execute an effective digital marketing strategy to assist with our social media advertising on top-of-funnel ad platforms such as Meta (Instagram/Facebook), Google, and YouTube.

All of this is in addition to the Company’s current sponsorships of various nationally recognized podcasts such as NoJumper and PlugTalk with Adam22, Pillow Talk with Ryan Pownall, OnlyStansby BarStool Sports and Glenny Balls, Monday Morning Podcast with Bill Burr, Fly on the Wall with Dana Carvey and David Spade, The Dale Jr Podcast with Dale Earnhard Jr., and We’re Here To Helpwith Jake Johnson and Gareth Reynolds.

The Company is consistently reviewing additional marketing and sponsorship opportunities to further enhance brand recognition throughout the 4th quarter and beyond.

• Global Expansion Opportunities: The Company has begun the process of identifying potential additional markets outside of the United States which it may seek to market and sell its Mango ED products in the future, with some of these markets requiring a doctor’s prescription (e.g., the United Kingdom) and others where ED products can be sold over the counter at local pharmacies (e.g., Mexico and other parts of South America). The Company’s decision to become the headline sponsor for the upcoming Raindance Film Festival in London is due to its interest in the United Kingdom as a potential viable option for global expansion.

Jacob Cohen, the Company’s Co-Founder and Chief Executive Officer stated, “We are extremely grateful to our loyal shareholders for your patience and commitment. We are fully dedicated to making Mango one of the top names in men’s health and wellness and we believe we have a strong plan to deliver on that commitment. As we approach the close of 2023, we believe we are finally beginning to see accelerating growth in brand recognition and revenues. We plan to continue to invest and reinvest in driving new customer acquisition in our flagship Mango ED products, funding permitting, while expanding into new verticals where our prior investments in the Mango brand are expected to have an established footprint with prospective customers. Stay tuned. The excitement is just beginning!”

MANGOCEUTICALS EXPANDS ITS MEN’S HEALTH PRODUCT LINE WITH COMPOUNDED HAIR GROWTH TREATMENT ‘GROW’ BY MANGORX

DALLAS, TX / ACCESSWIRE / November 16, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the expansion of its men’s health product line with the addition of its hair growth treatment, ‘Grow.’

The custom compounded hair growth treatment combines four clinically proven hair growth products – Minoxidil, Finasteride, Vitamin D3, and Biotin – encapsulated in convenient chewable, mint-flavored tablets. The product is now available for delivery by prescription through MangoRx’s website.

“The launch of ‘Grow’ signifies a giant step in the Company’s overall progress and mission to provide our customers with custom and innovative products and solutions under the MangoRx brand,” said Jacob Cohen, MangoRx’s co-founder and CEO. “When it comes to hair, we’re all about the upward and onward journey. Grow aligns with MangoRx’s mantra of performance, evolution, and achieving the best version of oneself. Unlike most of our competitors, we have reinforced our commitment and ongoing investment in providing oral dissolvable tablets with distinctive flavors. This ensures our customers avoid the hassle of messy topical treatments, preventing their hair from appearing wet and greasy. With Grow, it is confidence that’ll go to your head!”

Grow’s unique compounded formula combines Minoxidil, which encourages blood flow and follicle development, with Finasteride, blocking the formation of DHT (a known cause of male pattern baldness), along with supplements Vitamin D3, slowing hair-follicle calcification, and Biotin, which plays a crucial role in healthy hair growth. When combined, the four clinically proven hair growth products work to promote new growth in three to six months.

“As a healthcare provider, I offer my professional endorsement of this compounded oral dissolvable tablet as a valuable option for addressing hair loss concerns,” said Dr. Douglas Christianson, ND, advisory board member of MangoRx. “The meticulously formulated combination of Minoxidil, Finasteride, Biotin, and Vitamin D3 aligns with evidence-based approaches to hair restoration. This cutting-edge solution has demonstrated clinical efficacy in fostering hair regrowth and enhancing the overall health of the hair. It stands as a medically sound choice for individuals seeking to address hair loss.”

According to the American Hair Loss Association, by the age of 35 two-thirds of American men will experience some degree of increased hair loss, and by the age of 50, approximately 85 percent of men have significantly thinning hair. The process of male pattern baldness can begin before the age of 21 for approximately 25% percent of men.

Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

DAILY HAIR TREATMINT

GROW BY MANGORX

(4 Active Ingredients in 1)

BENEFITS:

Powerful Ingredients: Packed with Minoxidil, Finasteride, Vitamin D3, and Biotin for proven hair growth.

Regrow & Renew: Ingredients have been clinically shown to regrow hair in 3-6 months, stopping hair loss in its tracks.

Minty Freshness: Enjoy the burst of mint flavor as you chew your way to stronger hair!

Follicle Fuel: Boosts circulation to your hair roots, helping your mane thrive.

Monthly Magic: 30-day or 90-day supply to keep the good hair vibes flowing.

‍

OUR UNIQUE FORMULA

Grow by MangoRx is a uniquely compounded pharmaceutical hair growth formula housed in a sleek tin with a 30 or 90-day supply of chewable mint-flavored tablets. Infused with power-packed ingredients, Grow is designed to target the root causes of thinning hair and promote growth.

MINOXIDIL

Boosts circulation to follicles, helping them thrive and regrow hair in just 3-6 months.

FINASTERIDE

Targets male pattern hair loss by blocking the hormone responsible for hair growth interruption.

BIOTIN

Feeds your hair by aiding in keratin production, ensuring strands are healthy, strong, and shiny.

VITAMIN D3

An essential vitamin to nurture and strengthen hair, enhancing its natural resilience.

Grow by MangoRx, a proven blend of 4 hair growth ingredients, ensures that taking the steps toward a fuller head of hair has never been easier. Mint-flavored and easy to take, Grow by MangoRx is more than a product—it’s a promise to help you reclaim the hair you love. Join the revolution and let Grow bring your hair back to life!

MANGOCEUTICALS, INC.’S DEBUT COMMERCIAL SURPASSES 9.3 MILLION VIEWS ON YOUTUBE

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

Tapping into a market of more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico in 2024 and fueling International Sales Access Across Latin America

Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the establishment of its subsidiary, MangoRx Mexico, which will act as the lynchpin of the Company’s Mexican and expanded Latin American sales strategies for its Mango ED products.

The Company has engaged one of the largest international law firms, Diaz Reus International Law Firm, to establish its subsidiary presence in Mexico. With offices across five continents, Diaz Reus represents major Fortune 500 brands including Oracle, Nissan, Sony, and Allianz, to name a few.

“This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MangoRx’s Co-Founder and CEO. “First, ED medications – such as branded and generic Viagra (Sildenafil) and Cialis (Tadalafil) – are available to consumers over-the-counter in Mexico. That presents increased margin and sales volume potential for what we already produce and market here in the United States. Second, Mexico is a completely untapped market as our research indicates that we will be the only company offering an ED product in a flavored rapid-dissolve tablet (RDT).”

Next steps include establishing a manufacturing partner, applying for, and achieving certification with, the Comisión Federal para la Protección contra Riesgos Sanitarios (“COFEPRIS”), and establishing and formalizing distribution partnerships. The Company is already engaged in substantive negotiations with potential manufacturing partners, and it intends to formalize those relationships before the end of 2023.

Cohen added, “This is not a sudden shift. We have been working on this strategy since May 2023, and we are now in the final stages of cementing our lab partner for production, packaging, and fulfillment of products. We are also already in discussions with multiple potential distribution partners in Mexicowho have existing relationships with more than 40,000 pharmacies, retail outlets, and convenience stores across the country.”

In addition, achieving the COFEPRIS certification offers additional advantages for further expanding sales of MangoRx products internationally into other large and growing Latin American markets that offer ED medications as OTC products. Specifically, the COFEPRIS is recognized in the following additional countries: Columbia, Ecuador, El Salvador, Chile, Costa Rica and Panama.

MangoRx has hired market commercialization professional, Efraim (Efi) Karchmer, as President of MangoRx Mexico. Efi will be tasked with spearheading all initiatives involved in establishing the business operations of the new subsidiary. Mr. Karchmer has more than 25 years’ experience in sales, marketing, and distribution of diverse products in a multinational and multicultural environment.

According to a recent market study and analysis report conducted by Groupo Knobloch, the estimated annual market size in Mexico for ED pharmaceutical products is USD $216 million with approximately 24 million units sold annually and growing at a rate of 4% per year at an average sales price of USD $8.50 per unit.

“Adding a new and significant market segment with fundamental advantages over our core marketplace could be one of the most important and transformative strategic steps with have taken as a company,” concluded Cohen. “The path from here to full launch of Latin American sales for MangoRx products is a top priority, and we look forward to providing updates very soon.”

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

NEWS

PUBLISHED

6 DAYS AGO

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

PUBLISHED

NOV 29, 2023

MANGOCEUTICALS SELECTS TRYBE LABS AS ITS NATIONWIDE BLOOD COLLECTION AND TESTING SERVICES PROVIDER

PUBLISHED

NOV 16, 2023

MANGOCEUTICALS EXPANDS ITS MEN’S HEALTH PRODUCT LINE WITH COMPOUNDED HAIR GROWTH TREATMENT ‘GROW’ BY MANGORX

PUBLISHED

NOV 2, 2023

MANGOCEUTICALS, INC. LAUNCHES CHARITABLE INITIATIVE IN SUPPORT OF MEN’S HEALTH AWARENESS MONTH

PUBLISHED

OCT 26, 2023

MANGOCEUTICALS LAUNCHES TIKTOK INFLUENCER INITIATIVE AND BECOMES THE PRESENTING SPONSOR OF THE ONLY STANS PODCAST WITH GLENNY BALLS

PUBLISHED

OCT 19, 2023

MANGOCEUTICALS, INC. PROVIDES UPDATE TO SHAREHOLDERS ON Q3 ACHIEVEMENTS AND GUIDANCE ON YEAR END AND NEAR-TERM INITIATIVES

PUBLISHED

OCT 13, 2023

MANGOCEUTICALS ANNOUNCES TV AIR DATES FOR INTERVIEW FEATURING CEO JACOB COHEN ON BLOOMBERG TV AND FOX BUSINESS

PUBLISHED

OCT 12, 2023

MANGOCEUTICALS ANNOUNCES THE OFFICIAL LAUNCH OF MANGORX AFFILIATE MARKETING PROGRAM TO ENHANCE AND ACCELERATE TOPLINE GROWTH

PUBLISHED

SEP 14, 2023

MANGOCEUTICALS BRAND MANGORX ANNOUNCED AS RAINDANCE FILM FESTIVAL’S HEADLINE SPONSOR

PUBLISHED

SEP 7, 2023

MANGOCEUTICALS EXPANDS ITS NATIONWIDE MARKETING EFFORTS WITH A MULTIPLATFORM AUDIO POWERHOUSE ACROSS AMERICA

PUBLISHED

AUG 30, 2023

MANGOCEUTICALS LAUNCHES NEW HIGH-PRODUCTION QUALITY AD PROVIDING FRESH INSIGHT INTO ITS PROPRIETARY MANGO ERECTILE DYSFUNCTION PILL FORMULA

PUBLISHED

AUG 16, 2023

MANGOCEUTICALS LAUNCHES NEW SILDENAFIL BASED ERECTILE DYSFUNCTION PRODUCT WITH SIGNATURE MANGO FLAVOR & RAPID DISSOLVE

MANAGEMENT

JACOB COHEN

Co-Founder and Chief Executive Officer

Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.

Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.

From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.

Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.

Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.

JONATHAN ARANGO

Co-Founder and President

Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.

Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.

AMANDA HAMMER

Chief Operating Officer

Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams.

Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.

EUGENE M. JOHNSTON

Chief Financial Officer

Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company.

Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  

WE HAVE BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD FOR A ONE DAY MGRX PROFILE BY A THIRD PARTY, BULLZEYE  MEDIA, LLC.  WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD FOR A ONE DAY MGRX PROFILE BY A THIRD PARTY, BULLZEYE  MEDIA, LLC.

BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.

INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.

PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.

THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.

THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.

‍